Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | $25.4M | $54.4M | $90.1M | $132M | $204M | $245M | $313M | $377M |
| Revenue growth | — | 136.2% | 113.9% | 65.7% | 46.9% | 53.8% | 20.4% | 27.7% | 20.3% |
| Operating income | -$58.5M | -$70.6M | -$109M | -$140M | -$153M | -$235M | -$217M | -$221M | -$136M |
| Operating margin | -543.2% | -277.5% | -200.1% | -155.5% | -115.4% | -115.3% | -88.6% | -70.6% | -36.2% |
| Net income | -$59.3M | -$71.2M | -$108M | -$140M | -$152M | -$218M | -$205M | -$209M | -$77.7M |
| Net margin | -550.8% | -280.2% | -198.0% | -155.3% | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% |
| EPS (diluted) | -$24.49 | -$25.51 | -$3.92 | -$3.57 | -$3.15 | -$4.04 | -$3.60 | -$3.60 | -$1.30 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$51.3M | -$66.2M | -$87.9M | -$142M | -$112M | -$124M | -$142M | -$64.1M | -$47.6M |
| Capital expenditures | $6.59M | $3.69M | $14.8M | $9.87M | $27.1M | $102M | $27.8M | $5.08M | $28.0M |
| Free cash flow | -$57.9M | -$69.9M | -$103M | -$152M | -$139M | -$226M | -$170M | -$69.2M | -$75.6M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $31.2M | $80.8M | $46.7M | $93.7M | $466M | $379M | $286M | $226M | $183M |
| Total assets | — | $116M | $187M | $399M | $702M | $961M | $776M | $614M | $642M |
| Total liabilities | — | $26.7M | $34.9M | $62.6M | $121M | $172M | $153M | $142M | $169M |
| Long-term debt | — | $7.22M | $4.40M | $1.40M | — | — | — | — | — |
| Shareholders' equity | -$133M | -$201M | $152M | $336M | $581M | $789M | $623M | $473M | $473M |
| Retained earnings | — | -$211M | -$319M | -$458M | -$611M | -$828M | -$1.03B | -$1.24B | -$1.32B |
| Shares (wtd avg diluted) | — | 3.21M | 32.9M | 39.2M | 48.3M | 53.9M | 56.9M | 58.0M | 59.8M |
Every figure is extracted from Twist Bioscience Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.